New Hampshire Trust Reduces Holdings in Pfizer Inc. (NYSE:PFE)

New Hampshire Trust decreased its position in Pfizer Inc. (NYSE:PFEFree Report) by 20.7% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 37,674 shares of the biopharmaceutical company’s stock after selling 9,821 shares during the quarter. New Hampshire Trust’s holdings in Pfizer were worth $1,045,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of PFE. Advisor OS LLC raised its stake in Pfizer by 1.0% during the 4th quarter. Advisor OS LLC now owns 35,202 shares of the biopharmaceutical company’s stock valued at $1,013,000 after purchasing an additional 365 shares during the period. Safeguard Investment Advisory Group LLC increased its position in Pfizer by 3.9% in the 4th quarter. Safeguard Investment Advisory Group LLC now owns 9,987 shares of the biopharmaceutical company’s stock worth $288,000 after buying an additional 371 shares during the period. King Wealth Management Group raised its stake in Pfizer by 2.4% during the 4th quarter. King Wealth Management Group now owns 16,686 shares of the biopharmaceutical company’s stock valued at $480,000 after purchasing an additional 388 shares during the last quarter. Advance Capital Management Inc. lifted its stake in shares of Pfizer by 4.0% in the fourth quarter. Advance Capital Management Inc. now owns 10,177 shares of the biopharmaceutical company’s stock valued at $293,000 after buying an additional 391 shares during the period. Finally, Annis Gardner Whiting Capital Advisors LLC grew its holdings in shares of Pfizer by 1.4% during the 4th quarter. Annis Gardner Whiting Capital Advisors LLC now owns 28,952 shares of the biopharmaceutical company’s stock worth $834,000 after purchasing an additional 396 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of PFE traded up $0.18 during mid-day trading on Thursday, hitting $27.59. 8,629,842 shares of the company’s stock were exchanged, compared to its average volume of 41,059,598. The company has a quick ratio of 0.78, a current ratio of 1.05 and a debt-to-equity ratio of 0.66. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $39.24. The stock’s 50-day simple moving average is $27.61 and its 200-day simple moving average is $27.73. The firm has a market cap of $156.34 billion, a price-to-earnings ratio of -460.76, a price-to-earnings-growth ratio of 1.08 and a beta of 0.70.

Pfizer (NYSE:PFEGet Free Report) last issued its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, beating the consensus estimate of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The company had revenue of $14.88 billion during the quarter, compared to analysts’ expectations of $13.87 billion. During the same period in the previous year, the company earned $1.23 EPS. The business’s revenue for the quarter was down 19.5% compared to the same quarter last year. On average, equities research analysts expect that Pfizer Inc. will post 2.38 EPS for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, June 14th. Shareholders of record on Friday, May 10th were issued a $0.42 dividend. The ex-dividend date of this dividend was Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a yield of 6.09%. Pfizer’s payout ratio is presently -2,799.53%.

Analyst Ratings Changes

A number of research analysts have commented on PFE shares. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Morgan Stanley boosted their target price on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 2nd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Monday. BMO Capital Markets reaffirmed an “outperform” rating and issued a $36.00 target price (up from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Finally, Guggenheim initiated coverage on shares of Pfizer in a research note on Friday, February 23rd. They set a “buy” rating and a $36.00 price target for the company. Ten research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $35.86.

Get Our Latest Stock Analysis on PFE

About Pfizer

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Read More

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.